Shares of Hims & Hers Health dropped after JPMorgan lowered its price target from $35 to $33 following a mixed first-quarter report and a strategic shift from compounded to branded GLP-1 medications. Despite the cut, JPMorgan maintained an Overweight rating, while Canaccord raised its target to $32, viewing the quarter as a temporary setback. The company reported revenue growth but missed estimates, with margins compressing sharply. Management raised full-year revenue guidance and authorized a $250 million share buyback, signaling confidence beyond weight loss products. Investors should watch subscriber revenue trends and upcoming Q2 results to assess the success of the product transition and international expansion.
Bank of America lowered its price target for Hims & Hers Health to $30 from $32, maintaining a Neutral rating after the company's Q1 2026 results missed revenue and earnings expectations. The firm sees the need for a reset in market expectations due ...
Hims & Hers Health has been upgraded to a buy rating due to stronger-than-expected sales of its branded GLP-1 drug Wegovy, which shipped 125,000 units in six weeks. Management now expects over 100,000 monthly new weight-loss subscribers, restoring co...
Hims & Hers Health increased its full-year 2026 revenue guidance to $2.8-$3.0 billion despite reporting a quarterly EPS loss impacted by restructuring charges. The company showed strong subscriber growth nearing 2.6 million and high engagement with 9...
Hims & Hers shares fell about 14% in pre-market trading following a disappointing Q1 report, attributed to timing of the Novo Nordisk deal and tough year-over-year comparisons. Despite the initial drop, analysts see the Q2 guidance beat and raised fu...
Telehealth company Hims & Hers saw its stock fall 15.7% in premarket trading after reporting a first-quarter net loss of $92 million, nearly double last year's $50 million loss. Revenue rose 4% to $608 million, but average monthly revenue per subscri...
